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The product of the von Hippel-Lindau gene (VHL) acts as the substrate-recognition component of an E3
ubiquitin ligase complex that ubiquitylates the catalytic  subunit of hypoxia-inducible factor (HIF) for
oxygen-dependent destruction. Although emerging evidence supports the notion that deregulated accumulation
of HIF upon the loss of VHL is crucial for the development of clear-cell renal cell carcinoma (CC-RCC), the
molecular events downstream of HIF governing renal oncogenesis remain unclear. Here, we show that the
expression of a homophilic adhesion molecule, E-cadherin, a major constituent of epithelial cell junctions
whose loss is associated with the progression of epithelial cancers, is significantly down-regulated in primary
CC-RCC and CC-RCC cell lines devoid of VHL. Reintroduction of wild-type VHL in CC-RCC (VHL/) cells
markedly reduced the expression of E2 box-dependent E-cadherin-specific transcriptional repressors Snail and
SIP1 and concomitantly restored E-cadherin expression. RNA interference-mediated knockdown of HIF in
CC-RCC (VHL/) cells likewise increased E-cadherin expression, while functional hypoxia or expression of
VHL mutants incapable of promoting HIF degradation attenuated E-cadherin expression, correlating with
the disengagement of RNA polymerase II from the endogenous E-cadherin promoter/gene. These findings reveal
a critical HIF-dependent molecular pathway connecting VHL, an established “gatekeeper” of the renal epi-
thelium, with a major epithelial tumor suppressor, E-cadherin.
Individuals who inherit one faulty von Hippel-Lindau gene
(VHL) allele are predisposed to VHL disease, which is char-
acterized by the development of cerebellar, spinal, and retinal
hemangioblastoma, pheochromocytoma, and clear-cell renal
cell carcinoma (CC-RCC) (29). The tumor develops upon the
somatic loss of the remaining wild-type VHL allele in a sus-
ceptible cell. Importantly, biallelic loss of VHL is associated
with the vast majority of sporadic CC-RCCs, establishing VHL
as a critical suppressor of renal oncogenesis (29). CC-RCC is
resistant to conventional radiation and chemotherapies, and
approximately one-quarter of renal cancer patients present
with advanced disease, including locally invasive or metastatic
CC-RCC (12). Unfortunately, one-third of patients who un-
dergo surgical removal of localized tumors have recurrence of
the disease, and the median survival for patients harboring
metastatic CC-RCC is 13 months (12). Moreover, the principal
cause of morbidity and death of VHL patients is CC-RCC (29).
Despite the need to better understand the aggressive nature of
CC-RCC, the molecular pathways governing its malignant phe-
notype remain unresolved.
The most well-characterized function of VHL is as a sub-
strate-recognition component of the SCF (Skp1/Cdc53/F-box
protein)-like E3 ubiquitin ligase complex called ECV (elon-
gins/Cul2/VHL) that selectively ubiquitylates oxygen-depen-
dent prolyl-hydroxylated  subunits of hypoxia-inducible factor
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(HIF) (24, 26, 43, 49). Under hypoxic conditions, HIF is
stabilized, recruits p300/CBP, and binds to its constitutively
expressed partner HIF/arylhydrocarbon receptor nuclear
translocator (ARNT) (48). The heterodimeric HIF complex
binds to a consensus 5-RCGTG-3 hypoxia-responsive ele-
ment in enhancers and promoters to trigger the transcription
of numerous hypoxia-inducible genes that promote cellular
adaptation to hypoxia, enabling cell survival under compro-
mised oxygen availability (48). Concordantly, tumor cells de-
void of VHL have enhanced expression of HIF target genes,
such as VEGF (vascular endothelial growth factor; angiogen-
esis), GLUT-1 (glucose transporter 1; anaerobic metabolism),
and EPO (erythropoietin; production of oxygen-carrying red
blood cells), irrespective of oxygen tension (29). The overex-
pression of these and other hypoxia-inducible genes likely ex-
plains the angiogenic phenotype of VHL-associated tumors
and also supports the notion that constitutive stabilization of
HIF is causally linked to tumorigenesis. In support, Kaelin
and colleagues have shown that forced stable expression of
HIF-2 in CC-RCC cells ectopically expressing wild-type VHL
overrides the tumor suppressor capacity of VHL and restores
the tumorigenic potential of CC-RCC cells in an animal xe-
nograft system (32). Conversely, short hairpin RNA (shRNA)-
mediated knock-down of HIF-2 is sufficient to suppress the
tumorigenic capacity of RCC cells devoid of VHL (31). Nota-
bly, all CC-RCC-causing VHL mutants tested to date have
shown a failure in either assembling of ECV complex or bind-
ing to HIF (11, 21). However, the critical event(s) down-
stream of HIF that causes neoplastic transformation of proxi-
mal renal tubular epithelial cell (the origin of CC-RCC) is
unclear.
Proper regulation of cell-cell adhesion is vital during cell
growth, differentiation, and tissue development. E-cadherins,
homophilic adhesion molecules, and their associated catenins
are the major constituents of cell junctions in polarized epi-
thelial cells (46). Increased expression of E-cadherin is associ-
ated with the differentiation of mesenchymal cells into tubular
epithelial cells of the adult nephron. Conversely, loss of cell-
cell adhesion is frequently associated with tumor progression
and metastasis (46). In support of this paradigm, the loss of
E-cadherin is associated with the progression of numerous
carcinoma types, and forced expression of E-cadherin sup-
presses tumor development and invasion in various in vitro and
in vivo tumor model systems, establishing E-cadherin as a
critical tumor suppressor of the epithelium (46). Recently,
Krishnamachary et al. and Esteban et al. independently
showed that the loss of VHL in CC-RCC cells results in the
loss of E-cadherin expression in an HIF-dependent manner
(16, 34). Krishnamachary et al. argue that the regulation of
E-cadherin expression is exclusively HIF-1-dependent, while
Esteban et al. demonstrated dependency on both HIF-1 and
HIF-2 (16, 34). Furthermore, Krishnamachary et al. showed
that the activation of the HIF-1 pathway upon the loss of VHL
transactivates E-cadherin transcriptional repressors TCF3
(also known as E12/E47), ZFHX1A (EF1 or ZEB1), and
SIP1 (Smad-interacting protein-1; also known as ZEB-2 or
ZFHX1B), which correlated with the down-regulation of E-
cadherin transcription (34).
Here, we examined over 100 primary CC-RCC samples via
Affymetrix oligonucleotide arrays and show that the expression
of E-cadherin transcripts is significantly down-regulated in CC-
RCC. In addition, the analysis of 56 CC-RCC samples on
tissue microarrays and immunohistochemistry on CC-RCC ne-
phrectomy specimens from 13 patients revealed a strong pos-
itive correlation between the expression of VHL and E-cad-
herin. Small interfering RNA (siRNA)-mediated knockdown
of endogenous VHL or functional hypoxia resulted in dramatic
attenuation of E-cadherin expression. Importantly, reintroduc-
tion of wild-type VHL, but not a CC-RCC-causing VHL mu-
tant incapable of promoting HIF degradation, in CC-RCC
(VHL/ HIF-1/) cells fully restored E-cadherin expres-
sion, in part, via HIF-dependent regulation of E2 box-depen-
dent transcriptional repressors Snail and SIP1 but not Slug,
TCF3, or ZFHX1A, and subsequent engagement of RNA
polymerase (Pol) II on endogenous E-cadherin promoter/gene.
These findings provide a compelling molecular mechanism
governing the transcription of E-cadherin by the VHL-HIF
pathway and strengthen the potential involvement of E-cad-
herin in the development of CC-RCC.
MATERIALS AND METHODS
Cells. HEK293A embryonic kidney cells, U2OS osteosarcoma, and 786-O
(VHL/) renal clear-cell carcinoma cell lines were obtained from the American
Type Culture Collection (Rockville, MD) and maintained in Dulbecco’s modi-
fied Eagle’s medium (DMEM) supplemented with 10% heat-inactivated fetal
bovine serum (Sigma) at 37°C in a humidified 5% CO2 atmosphere. 786-O
subclones ectopically expressing wild-type hemagglutinin (HA)-VHL (786-VHL)
or mutant HA-VHL(C162F) or HA-VHL(L188V) were previously described
(21, 39). RCC4 (VHL/) renal clear-cell carcinoma subclones stably expressing
HA-VHL (RCC4-VHL) or empty plasmid (RCC4-MOCK) were previously de-
scribed (43). 786-VHL cells stably expressing HIF-2(P531A) (786-VHLHIF-
2) or empty control (786-VHLMOCK) via retrovirus were previously
described (32) and were generously provided by William G. Kaelin. 786-O
subclones stably expressing pRetroSUPER-empty or pRetroSUPER-HIF2
shRNA were previously described (31).
Antibodies. Monoclonal anti-HA antibody (12CA5) was obtained from Roche
Molecular Biochemicals. Monoclonal anti-VHL antibody (IG32) was as previ-
ously described (30). Anti--catenin, anti-lamin A/C, and anti--tubulin antibod-
ies were obtained from Santa Cruz (Santa Cruz, CA), Abcam (Cambridge, MA),
and Sigma-Aldrich (Oakville, Ontario, Canada), respectively. Anti-E-cadherin
antibody was obtained from BD Transduction Labs (Mississauga, Canada). Anti-
HIF-2 antibody was obtained from Novus Biologicals Inc. (Littleton, CO).
Plasmids. Mammalian expression plasmid pRc-CMV-HA-VHL(WT) was de-
scribed previously (39). Expression plasmid encoding Snail was generously pro-
vided by Paul Hamel. E-cadherin core promoter (308/21)-luciferase reporter
plasmids (E-cad prom-luc wild type [WT] or mutE2, which contains inactivating
mutations in both E2 boxes) and expression plasmids encoding SIP1 were pre-
viously described (13). Plasmids containing shRNA against E-cadherin were
generated using the Invitrogen pENTR/U6 system. Inserts containing hairpin
DNA were generated using Invitrogen’s Block iT siRNA designer, and insert
cassettes were bought polyacrylamide gel electrophoresis (PAGE) purified from
Invitrogen using the pENTR recommended protocol. The four generated
shRNAs were chosen based on their predicted ability of silencing and their
placement within the E-cadherin transcript. Each shRNA has 21 mer of com-
plementary sequences starting at positions 1184, 1660, 1973, and 2128 of the
E-cadherin gene (accession number NM004360). A CGAA loop is included in all
plasmids. The nontargeting or scrambled shRNA was created in a similar manner
with a sequence of 5-GGAGCACGGTATTCGGGTCTACTAA-3, which
bears no sequence similarity with the E-cadherin transcript.
Immunoprecipitation and immunoblotting. Immunoprecipitation and West-
ern blotting were performed as described previously (50). In brief, cells were
lysed in EBC buffer (50 mM Tris [pH 8.0], 120 mM NaCl, 0.5% NP-40) supple-
mented with a cocktail of protease and phosphatase inhibitors (Roche, Laval,
Canada). Immunoprecipitates immobilized on protein A-Sepharose beads (Am-
ersham Biosciences, Piscataway, NJ) were washed five times with NETN buffer
(20 mM Tris [pH 8.0], 120 mM NaCl, 1 mM ETDA, 0.5% NP-40), eluted by
boiling in sodium dodecyl sulfate (SDS)-containing sample buffer, and size-
fractionated by SDS-PAGE. Resolved proteins were then electrotransferred
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onto polyvinylidene difluoride membrane (Bio-Rad Laboratories, Hercules,
CA), immunoblotted with the various antibodies, and visualized by chemilumi-
nescence (Amersham Biosciences, Piscataway, NJ).
Hypoxia treatment of cells. Cells were maintained at 1% O2 for the times
indicated in the legend to Fig. 6 in a ThermoForma (Marietta, OH) hypoxia
chamber (5% CO2, 10% H2, 85% N2). Cell lysates were prepared in the chamber
in hypoxic environment prior to further experimentation.
Immunohistochemical staining. Formalin-fixed paraffin-embedded sections
from 13 nephrectomy specimens with renal cell carcinoma of clear-cell type
(CC-RCC) were obtained from the files of The Department of Pathology and
Laboratory Medicine at The University Health Network (Toronto, Canada).
These tissue blocks were used and processed in accordance with a University
Health Network Research Ethics Board-approved protocol concerning gene
expression in renal cell carcinoma. Tissues were fixed in 10% neutral buffered
formalin for 24 to 36 h. Representative sections of tumor with adjacent nontumor
renal parenchyma, 3 to 4 mm in thickness, were embedded in paraffin, and 5-m
sections were cut and placed on coated slides for light microscopy. Tumor
morphology and classification were assessed using standard hematoxylin and
eosin staining. The tumors were classified as CC-RCC according to criteria
described in the World Health Organization classification of renal tumors (15).
Immunohistochemical staining for E-cadherin and VHL was performed manu-
ally using a standard avidin-biotin-peroxidase complex method. Sections were
incubated overnight in a humidified chamber with either unlabeled mouse anti-
human E-cadherin or mouse anti-human VHL antibodies, each at a 1:2,000
dilution, following microwave pretreatment for antigen retrieval. The sections
were then incubated with a biotinylated secondary antibody (horse anti-mouse
immunoglobulin G at a dilution of 1:200) and the avidin-peroxidase complex.
The color reaction was visualized using diaminobenzidine as the chromogen. The
tissue was then lightly counterstained with hematoxylin.
TMAs. Tissue microarrays (TMAs) consisting of quadruplicate representative
1.0-mm cores from 56 CC-RCCs with various Fuhrman grades (grades 1 to 4)
and stages (pT1-pT4) were used to analyze the correlation between E-cadherin
and VHL protein expression patterns. Five-micrometer sections from the CC-
RCC TMAs were stained with anti-E-cadherin and anti-VHL antibodies as
described above in “Immunohistochemical staining.” The slides were then
scanned using a ScanScope (Aperio Technologies, Vista, CA) and scored by two
observers. In order to be considered for evaluation, at least half of the TMA core
was required to be present on the slide with at least 50% of the tissue present
being tumor cells. Cores were scored as being either positive or negative. Only
tumors with three or more cores in agreement were used for further analysis.
Based on these criteria, 70% (39 out of 56) of the tumors on the TMA were
suitable for the correlation analysis between E-cadherin and VHL.
Migration assay. Cells were seeded on uncoated six-well plates, and scraping
the cells with a sterile pipette tip generated the wounds. Cells were washed once
and maintained in warm DMEM containing 0.5% fetal bovine serum (FBS) for
the duration of the migration assay. A Nikon Eclipse TE200 inverted microscope
equipped with a heated stage and a Hamamatsu digital camera (model C4742-
95) was used to capture the images at the time points indicated in the legend to
Fig. 3. Each wound measurement was taken in triplicate, and the experiment was
repeated three times. Percent wound closure was determined by the measure-
ment of the surface area of the wound at various time points relative to the
starting wound surface area using the AxioVision AC program (version 4.2.0.0).
Invasion assay. BioCoat Matrigel Invasion Chambers (BD Biosciences) con-
taining inserts with a matrigel and an underlying membrane with 8-m pores
were used as previously described (35). Briefly, the inserts were hydrated with
warm DMEM without FBS in 5% CO2 at 37°C for two hours. A total of 2.5 
104 cells were seeded into the upper chamber containing DMEM with no FBS,
and the lower chamber contained DMEM with 10% FBS. Cells were incubated
at 37°C in 5% CO2 for 22 h. Noninvading cells were removed from the upper
membrane by scrubbing with a cotton swab. The invading cells were fixed with
95% ethanol, stained with 0.1% crystal violet (Sigma), and visualized under an
inverted light microscope. Cells were counted from photographs of the mem-
brane and each experiment was repeated twice.
Subcellular fractionation. Cells were resuspended in buffer A (10 mM HEPES
[pH 7.9], 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol) supple-
mented with protease and phosphatase inhibitors (Roche, Laval, Canada) and 1
mM dithiothreitol (DTT) and subsequently lysed with 0.1% Triton X-100. Sam-
ples were incubated for 7 min on ice and centrifuged. While the supernatant was
recovered (cytoplasmic fraction), the pellet was washed with buffer A and resus-
pended in buffer B (0.2 mM EGTA [pH 8], 3 mM EDTA [pH 8]) supplemented
with protease and phosphatase inhibitors (Roche, Laval, Canada) and 1 mM
DTT. After a 30-min incubation period, samples were centrifuged, and the
resulting supernatant was isolated (nuclear fraction).
Dual-luciferase assay. U2OS osteosarcoma cells grown on six-well plates were
transfected with a total of 2.5 g of expression plasmids using Fugene 6 (Roche).
E-cad prom-luc WT or mutE2 (0.9 g per transfection) was used to measure
E-cadherin core promoter-mediated transcription, and 0.1 g of the Renilla
luciferase plasmid, pRL-SV40 (Promega), was used as a transfection control. An
empty pcDNA3.1 plasmid (Invitrogen) was used to maintain a constant final
amount of transfected DNA. Cells were lysed 48 h after transfection, and lucif-
erase assays were performed using the Dual-Luciferase Reporter Assay system
(Promega), and relative light units (RLUs) were measured using a Lumat
LB9507 luminometer (Berthold Technologies). Firefly luciferase RLUs were
normalized against Renilla luciferase RLUs and standardized to the result of
transfection with only the E-cad prom-luc WT, which was arbitrarily set to 1.0.
Experiments and transfections were performed in triplicate with one represen-
tative experiment presented. Error bars represent standard deviations.
Microarray analysis. We have established a large gene expression profiling
database of renal tumors, some of which have previously been published (18, 63).
For this study, we selected a total of 105 renal tumors of clear-cell type and 12
normal kidney tissue samples. The Affymetrix HGU133 Plus 2.0 GeneChip
oligonucleotide arrays were used for all 117 cases. The HGU133 Plus 2.0 arrays
contain 54,675 probe sets, representing approximately 47,000 transcripts and
variants. The manufacturer’s recommended protocol (1) was followed for ex-
pression profiling. Briefly, for oligonucleotide expression profiling, 5 to 20 g of
total RNA was used to prepare antisense biotinylated RNA. A subset of cases
was spiked with external poly(A) RNA positive controls (Affymetrix, Santa
Clara, CA). Synthesis of cDNA was performed with the use of T7-oligo(dT)
primer. In vitro transcription was performed using a Bioarray Transcript Label-
ing Kit (Enzo, New York). The biotinylated cRNA was subsequently fragmented,
and 15 g was hybridized to each array at 45°C for 16 h. Scanning was performed
in a GeneChip 3000 scanner. Quality assessment was performed in a GeneChip
Operating System 1.4 (Affymetrix) using global scaling to a target signal of 500.
Quality assessment was also performed using denaturing gel electrophoresis.
Median background was 73, the median scaling factor was 3.06, and the median
GADPH (glyceraldehyde-3-phosphate dehydrogenase) 3/5 ratio was 1.03, in-
dicative of a high overall array and RNA quality.
Statistical analyses were performed in the statistical environment R 2.2, uti-
lizing packages from the Bioconductor project. The MAS 5 algorithm was used
to perform preprocessing of the CEL files, including background adjustment,
quartile normalization, and summarization. The means and the standard errors
for E-cadherin gene expressions were calculated for each of the group of samples.
A two-tailed Student’s t test was used to determine statistically significant dif-
ferences between various groups.
siRNA-mediated VHL knockdown. siGENOME SMARTpool targeted to VHL
was used (Dharmacon, Austin, TX). A nontargeting scrambled siRNA duplex
was used as a negative control (5-CCAUUCCGAUCCUGAUCCG-3).
HEK293A (VHL/) cells grown on six-well tissue culture plates were trans-
fected with scrambled and VHL siRNA at a final concentration of 200 nM.
Briefly, 8 l of Oligofectamine (Invitrogen) was incubated with 48 l of Opti-
MEM I (Gibco/Invitrogen) for 8 min. The Oligofectamine mixture was added to
the siRNA diluted in 175 l of Opti-MEM I and incubated for 20 min before
adding the resulting mixture to 800 l of Opti-MEM I into the wells. After 3 h,
300 l of DMEM containing 30% heat-inactivated FBS (Sigma) was added to the
plates. RNA was extracted 48 h after transfection using an RNeasy kit (QIAGEN,
Mississauga, Ontario, Canada) treated with RNA-free DNase (Ambion, Texas), and
first-strand cDNA synthesis was performed.
Quantitative real-time PCR. For first-strand cDNA synthesis, 1 l of oli-
go(dT)23 primer (Sigma) was incubated with 5 g of RNA and distilled H2O
(total reaction volume of 20 l) for 10 min at 70°C in a thermal cycler (MJ
Research, Boston, MA). The mixture was cooled to 4°C, at which time 4 l of 5
first-strand reaction buffer, 2 l of 0.1 M DTT, 1 l of a 10 mM concentration of
each deoxynucleoside triphosphate, and 1 l of Superscript II reverse transcrip-
tase (Invitrogen) were added. cDNA synthesis was performed for 1.5 h at 42°C,
followed by 15 min at 70°C in the thermal cycler. Human genomic DNA stan-
dards (human genomic DNA was obtained from Roche, Mannheim, Germany)
or cDNA equivalent to 20 ng of total RNA were added to the quantitative PCR
(qPCR) reaction mixture in a final volume of 10 l containing 1 PCR buffer
(without MgCl2), 3 mM MgCl2, 0.25 units of Platinum Taq DNA polymerase, a
0.2 mM concentration of each deoxynucleoside triphosphate, 0.3 l of SYBR
Green I, 0.2 l of ROX reference dye, and a 0.5 M concentration of each
primer (Invitrogen). Amplification conditions were as follows: 95°C (3 min), 40
cycles of 95°C (10 s), 65°C (15 s), 72°C (20 s), and 95°C (15 s). qPCR was
performed using the ABI Prism 7900HT Sequence Detection System (Applied
Biosystems, Foster City, CA). Gene-specific oligonucleotide primers designed
using Primer Express (Applied Biosystems) were as follows: Snail primer set
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(5-TTCAACTGCAAATACTGCAACAAG-3 and 5-CGTGTGGCTTCGGA
TGTG-3), SIP1 primer set (5-CCACACTTCGCGGCTTCTT-3 and 5-CGA
TCTGCGAAGTCTTGTTTGT-3), E-cadherin primer set (5-GTCATCCAAC
GGGAATGCA-3 and 5-TGATCGGTTACCGTGATCAAAA-3), GLUT-1
primer set (5-CACCACCTCACTCCTGT-TACTT-3 and 5-CAAGCATTTC
AAAACCATGTTTCTA-3), VEGF primer set (5-CTCTCTCCCTCATCGGT
GACA-3 and 5-GGAGGGCAGAGCTGAGTGTTAG-3), and U1AsnRNP1
primer set (5-CAACGACAGCCGAGACATGTA-3 and 5-AGCCTCCATCA
AATACCCATTC-3). SYBR Green I fluoresces during each cycle of the qPCR
by an amount proportional to the quantity of amplified cDNA (the amplicon)
present at that time. The point at which the fluorescent signal is statistically
significant above background is defined as the cycle threshold (CT). Expression
levels of the various transcripts were determined by taking the average CT value
for each cDNA sample performed in triplicate and measured against a standard
plot of CT values from amplification of serially diluted human genomic DNA
standards. Since the CT value is inversely proportional to the log of the initial
copy number, the copy number of an experimental mRNA can be obtained from
linear regression of the standard curve. A measure of the relative difference in
copy number was determined for each mRNA. Values were normalized to
expression of U1AsnRNP1 mRNA, expressed relative to scrambled siRNA sam-
ples (arbitrarily set to 1.0), and represented as the mean value of three indepen-
dent experiments performed in triplicate 	 standard deviations.
ChIP. Chromatin immunoprecipitation (ChIP) was performed as published
previously using the Upstate ChIP assay kit (17). Five micrograms of anti-RNA
polymerase II (N-20) antibody (Santa Cruz) was added to sheared, formaldehyde
cross-linked chromatin preparations from 1  106 cells, and immunoprecipita-
tion was performed overnight at 4°C. A control immunoprecipitation without the
addition of antibody was also performed in parallel. An 18-l aliquot (of a total
of 1,800 l) of chromatin was removed prior to immunoprecipitation to serve as
an input control. The cross-links were reversed by addition of 2 l of 5 M NaCl,
and the sample was diluted 1 in 10 before real-time PCR was performed.
Immune complexes were collected with protein A-agarose beads, and, after
extensive washing, immune complexes were released, formaldehyde cross-links
were reversed, and DNA was purified by phenol-chloroform extraction. Follow-
ing ethanol precipitation, DNA was resuspended in 30 l of water. Real-time
PCR was performed on 2 l of anti-Pol II immunoprecipitated DNA, 2 l of
no-antibody control, and 2 l of the diluted input sample. Real-time PCR was
performed in triplicate using SYBR green chemistry. Copies of the target gene
were determined using genomic DNA as a standard curve (where 1 ng of
genomic DNA is equivalent to 300 copies of a single copy gene). Immunopre-
cipitated DNA (IP DNA) was determined by subtracting the number of copies of
the no-antibody control from the anti-Pol II immunoprecipitated DNA and
dividing by the number of copies in the diluted input sample. Primers were
designed to amplify the human E-cadherin promoter (forward, 5-CCACGCAC
CCCCTCTCAGT-3; reverse, 5-GAGCGGGCTGGAGTCTGAAC-3), hu-
man E-cadherin exon 10 (forward, 5-CCGTGGATGTGCTGGATGTGA-3;
reverse, 5-TGGGCAGTGTAGGATGTGATTTC-3), and the human cyclophi-
lin A promoter (forward, 5-CCTCATGTGTCGTCCCCATCA-3; reverse, 5-C
GCCCGTTTTATACCACGTTCG-3).
RESULTS
Expression of E-cadherin is down-regulated in CC-RCC and
correlates with VHL status. We have established a large gene
expression profiling database of renal tumors, some of which
have previously been published (18, 63). For this study, we
FIG. 1. Expression of E-cadherin is down-regulated in CC-RCC and correlates with VHL status. (A) 105 CC-RCC tumor samples and 12
normal kidney tissue samples were analyzed using Affymetrix HGU133 Plus 2.0 GeneChip oligonucleotide arrays. Mean E-cadherin expression and
standard error were calculated, and a two-tailed Student’s t test was used to determine statistical significance between the two groups. (B) Im-
munohistochemical staining of a representative CC-RCC with anti-E-cadherin and anti-VHL antibodies. Note the negative staining of the tumor
cells (upper right in each image) with each marker, in contrast to the positive staining shown by core tubule epithelium in the adjacent nontumor
renal cortex (lower left in each image) (original magnification, 50). (C) TMAs containing 56 CC-RCC were immunostained with anti-VHL and
anti-E-cad antibodies. The slides were then scanned using Aperio ScanScope and scored blind by two independent observers as being either
positive or negative. Tumor cores meeting the quality standard criteria (see Materials and Methods) were considered for the correlation analysis
(bar graph). Representative cores of CC-RCC on TMAs stained with anti-VHL and anti-E-cadherin antibodies are shown where the top row
depicts a representative core showing negative staining for VHL and E-cadherin and the bottom row depicts a representative core showing positive
staining for VHL and E-cadherin. Tumor morphology and classification were assessed using standard hematoxylin and eosin staining.
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selected a total of 105 human renal tumors of clear-cell type
and 12 normal kidney tissue samples. Using the Affymetrix
HGU133 Plus 2.0 GeneChip oligonucleotide arrays for all 117
cases, we found that the expression of E-cadherin transcripts
was significantly down-regulated in CC-RCC (Fig. 1A). This is
consistent with immunohistochemical studies that showed re-
duced E-cadherin staining in the vast majority of CC-RCC
tumor samples and cell lines tested (45, 58). However, the
molecular mechanism that accounts for the frequent loss of
E-cadherin in CC-RCC is unknown.
To date, VHL is the most frequently mutated gene in CC-
RCC, and biallelic inactivation of the VHL locus is associated
with the development of greater than 80% of sporadic CC-
RCC. Thus, we asked whether the expression of E-cadherin is
associated with the VHL status. Hematoxylin and eosin stain-
ing of representative sections from nephrectomy specimens
from 13 patients confirmed the characteristic morphological
features of CC-RCC including nests of cells with abundant,
optically clear cytoplasm and delicate cell membranes sur-
rounded by a network of small, thin-walled blood vessels (data
not shown). Each section studied by immunohistochemistry
contained normal renal parenchyma including core convoluted
tubules within the renal cortex (Fig. 1B, left lower half of the
micrograph) adjacent to CC-RCC (right upper half of the
micrograph). Membranous anti-E-Cadherin staining and cyto-
plasmic/membranous anti-VHL staining shown by core convo-
luted tubules were used as internal positive controls on each
slide. Cells in this representative tumor sample showed correl-
ative staining for E-cadherin and VHL, where negative stain-
ing for VHL observed in CC-RCC corresponded with mark-
edly reduced staining of E-cadherin (Fig. 1B, compare upper
and lower panels).
To further validate the positive correlation between VHL
and E-cadherin expression, TMAs consisting of 56 CC-RCC
cores in quadruplicate were generated. Thirty-nine of the CC-
RCC samples met the quality standard criteria (see Materials
and Methods) and were analyzed for E-cadherin and VHL
protein expression patterns. While only 33% (5/15) of the
tumors that stained negative for VHL (15/39) stained positive
for E-cadherin, the majority (67% or 16/24) of tumors that
stained positive for VHL (24/39) also stained positive for E-
cadherin (Fig. 1C). However, a positive stain for VHL does not
formally indicate the presence of a wild-type VHL, as, for
example, a subtle point mutation will likely produce a positive
staining signal. Thus, additional mutational analysis will be
required to generate a more precise E-cadherin:VHL correla-
tion index.
FIG. 2. Loss of VHL results in down-regulation of E-cadherin. (A) VHL/ 786-O and RCC4 cells stably expressing wild-type VHL or empty
plasmid (MOCK) were lysed, equal amounts of total cellular lysates were separated by SDS-PAGE, and immunoblotted with the indicated
antibodies. Anti--tubulin immunoblotting was performed as an internal loading control. (B) Expression of E-cadherin was measured by
quantitative real-time PCR in 786-MOCK and 786-VHL cells and normalized to U1AsnRNP1 mRNA level. The E-cadherin level in 786-VHL cells
was arbitrarily set to 1.0. Error bars represent standard deviations of the relative increases in expression between the indicated cell types over three
independent experiments. (C) Endogenous VHL in HEK293A cells was knocked down using VHL-specific siRNA or scrambled nontargeting
control siRNA. RNA was then extracted for cDNA synthesis and endogenous transcript levels of VHL, E-cadherin, and U1AsnRNP1 measured.
Error bars represent standard deviations of the relative increases between the expression of the indicated mRNA relative to its expression using
control siRNA (arbitrarily set to 1.0) over three independent experiments.
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Knockdown of endogenous VHL results in a dramatic at-
tenuation of E-cadherin expression. Reconstitution of 786-O
(VHL/ HIF-1/) or RCC4 (VHL/) renal carcinoma
cells with HA-VHL dramatically restored the expression of
E-cadherin protein and mRNA, as measured by Western blot-
ting and quantitative real-time PCR, respectively (Fig. 2A and
B). In addition, siRNA-mediated knockdown of endogenous
VHL in HEK293A embryonic kidney cells resulted in marked
down-regulation of E-cadherin expression (Fig. 2C). Microar-
ray (Fig. 1A) and real-time PCR data strongly suggest that
E-cadherin regulation by VHL is at the pretranslational level.
The cytoplasmic domain of E-cadherin is in a complex with
-catenin, implicating a potential “outside-in” signaling where
a loss of E-cadherin would release -catenin to associate with
the leukocyte enhancer factor /T-cell factor to regulate the
transcription of cell cycle-related genes (e.g., cyclin D1) or
invasion-related genes (e.g., metalloproteinase matrilysin and
fibronectin) (46). Interestingly, an increased level of cyclin D1
has been observed in RCC cells devoid of VHL at high cell
density (4), and cells expressing tumor-causing VHL mutants
fail to assemble proper extracellular fibronectin matrices (50,
62). However, both the overall expression and subcellular lo-
calization of -catenin remained unaffected by VHL (Fig. 2A
and see Fig. S1 in the supplemental material), suggesting that
-catenin-mediated transcription is likely not involved in po-
tential outside-in signaling via the loss of E-cadherin in the
context of CC-RCC.
shRNA-mediated down-regulation of E-cadherin increases
the invasive potential of CC-RCC. The role of E-cadherin in
modulating the migration and invasion properties of epithelial
cells is well established. However, it is not known whether
E-cadherin has similar biological effects in the context of kid-
ney epithelial cells or CC-RCC. Although E-cadherin expres-
sion can be predictably determined by manipulating the status
of VHL, altering the expression level of VHL has other con-
sequences that can influence the motility and invasion proper-
ties of CC-RCC (see Discussion). Thus, we used an shRNA
approach to specifically down-regulate the endogenous expres-
sion level of E-cadherin in HEK293A embryonic kidney epi-
thelial cells, which resulted in a significant enhancement of
migration as measured by percent wound closure (61.2% 	
4.8%) compared to cells expressing scrambled shRNA
(43.0% 	 3.0%) (Fig. 3A and B). The change in motility was
noticeable from the early time points, suggesting that the effect
of modulating the expression of E-cadherin is not only potent
but also immediate (Fig. 3C). shRNA-mediated down-regula-
tion of E-cadherin consistently increased the motility of 786-
VHL cells in a similar wound assay but was not statistically
significant (data not shown). However, the invasion potential
was increased (2.4 	 0.2)-fold in comparison to 786-VHL cells
expressing the scrambled shRNA, as measured on the standard
matrigel invasion chambers (Fig. 3D and E). It should be noted
that the changes in motility and invasion are likely underesti-
mated due to the incomplete knockdown of E-cadherin (Fig.
3A and D). Nevertheless, these results suggest that the dimi-
nution of E-cadherin expression would promote the invasive
property of CC-RCC.
VHL regulates E-cadherin expression via an HIF-dependent
mechanism. We next asked whether the regulation of E-cad-
herin expression by VHL is mediated through the activity of
HIF. RCC4-VHL and 786-VHL cells were maintained under
normoxic (21% oxygen) (Fig. 4A) or hypoxic (1%) (see Fig. S2
in the supplemental material) conditions for 16 h and analyzed
by Western blotting. The expression of E-cadherin was dra-
matically reduced under hypoxia while preserving the expres-
sion status of VHL (Fig. 4A). The effect of hypoxic treatment
was confirmed by the increase in HIF-2 expression (Fig. 4A).
Although this result suggests that hypoxia-induced stabiliza-
tion of HIF results in repression of E-cadherin expression, it is
formally possible that VHL, independent of HIF, regulates the
expression of E-cadherin in an oxygen-dependent manner.
Therefore, we examined various VHL mutants that have re-
tained or lost the ability to regulate HIF. Certain non-CC-
RCC-associated VHL mutants have been shown to retain the
ability to regulate HIF activity (11, 21, 62). For example, The
L188V mutation allows proper oxygen-dependent degradation
of HIF and is associated with a subclass of VHL disease (type
2C), which is clinically characterized by the exclusive develop-
ment of pheochromocytoma (21). In contrast, invariably all
CC-RCC-associated VHL mutations tested to date, such as
C162F, result in a complete loss of the ability to mediate the
destruction of HIF via the ubiquitin-proteasome pathway (11,
21). 786-O cells ectopically expressing VHL(C162F) showed
negligible expression of E-cadherin, while those expressing
VHL(L188V) showed higher detectable levels of E-cadherin,
albeit at a lower level than observed in cells expressing
VHL(WT) (Fig. 4B). In addition, 786-O (VHL/ HIF-1/)
cells stably expressing wild-type VHL (786-VHL) infected with
retroviruses that express functional and stable HIF-2(P531A)
(escapes VHL recognition) demonstrated a reduced level of
E-cadherin relative to 786-VHL cells infected with “empty”
retrovirus (Fig. 4C, compare lanes 1 and 2). Notably, the level
of E-cadherin was inversely proportional to the level of
HIF-2 (Fig. 4C). Conversely, 786-O subclones infected
with retroviruses that express HIF-2-specific shRNA dem-
onstrated a markedly increased level of E-cadherin relative
to 786-O cells infected with empty retrovirus (Fig. 4D). In
addition, the activity of the exogenous E-cadherin promoter-
driven luciferase reporter was much higher in 786-O cells
reconstituted with wild-type VHL (786-WT; low HIF activ-
ity) than in 786-MOCK (high HIF activity) cells (Fig. 4E).
Taken together, these results strongly suggest that HIF neg-
atively regulates E-cadherin expression, at least in part, at
the level of transcription.
VHL down-regulates E-cadherin-specific transcriptional re-
pressors Snail and SIP1. Mutational analyses have shown that
biallelic somatic inactivating mutations of E-cadherin are rare
(7, 8), and emerging evidence suggests that the loss or reduc-
tion in E-cadherin expression in cancer cells primarily occurs at
the level of transcription (6, 19, 28, 65). The two major regu-
lators of E-cadherin transcription are the zinc finger transcrip-
tional repressors Snail and SIP1, which bind evolutionarily
conserved E2 boxes located within the E-cadherin core pro-
moter resulting in the inhibition of E-cadherin transcription (5,
10, 13). Moreover, hypoxic treatment of ovarian carcinoma
cells was shown to attenuate the expression of E-cadherin via
the upregulation of Snail (23).
Quantitative real-time PCR analysis showed a significant
attenuation of both Snail and SIP1 in CC-RCC 786-O cells
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FIG. 3. Down-regulation of E-cadherin increases the migration of embryonic kidney cells and invasion of CC-RCC cells. (A) HEK293A cells were
transiently transfected with a plasmid encoding the scrambled shRNA or a cocktail of four E-cadherin-specific shRNAs. Equal amounts of the whole-cell
lysates were immunoprecipitated with an anti-E-cadherin antibody, resolved by SDS-PAGE, and immunoblotted with an anti-E-cadherin antibody. Equal
amounts of the remaining whole-cell lysates were resolved by SDS-PAGE and immunoblotted with an anti-
-tubulin antibody. E-cadherin signal
intensities were quantified using a Kodak Image Station 2000R densitometer and normalized against the corresponding 
-tubulin signals; values are
indicated in the parentheses. (B) Wounds were created 48 h posttransfection with the indicated plasmids. Percent wound closure was determined by
measuring the migration of cells from the wound edge 25 h postwound scrape. Each wound measurement was taken in triplicate, and the experiment was
repeated three times. (C) Line graph representing early migration profile, as indicated by percent wound closure, as measured in the experiment shown
in panel B, of HEK293A cells transfected with the indicated shRNA plasmids. (D) 786-VHL cells were transiently transfected with a plasmid encoding
the scrambled shRNA or a cocktail of four E-cadherin-specific shRNAs. Equal amounts of the whole-cell lysates were immunoprecipitated with an
anti-E-cadherin antibody, resolved by SDS-PAGE, and immunoblotted with an anti-E-cadherin antibody. Equal amounts of the remaining whole cell
lysates were resolved by SDS-PAGE and immunoblotted with an anti-hnRNP antibody. E-cadherin signal intensities were quantified using a Kodak
Image Station 2000R densitometer and normalized against the corresponding hnRNP signals; results are given in parentheses. (E) 786-VHL cells were
transiently transfected with the indicated plasmids as shown in panel D. Cells were counted 72 h posttransfection, and 2.5  104 cells were seeded into
BD Matrigel Invasion Chambers and incubated for 22 h. The invading cells were stained with 0.1% crystal violet, and images were captured under an
inverted light microscope. Cells were counted from photographs of the membrane, and each experiment was repeated twice. The relative change in
invasion was determined by counting the number of invading cells transfected with E-cadherin-specific shRNA and normalizing the value against the
number of invading cells transfected with the scrambled shRNA (arbitrarily set at 1.0). Anti-E-cad, anti-E-cadherin; IP, immunoprecipitation; IB,
immunoblot; Anti-Tub, anti-
-tubulin; shE-cad, E-cadherin-specific shRNA; shScram, scrambled shRNA; T, time.
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restored with VHL (Fig. 5A). However, negligible changes in
the expression were noted for the other known E-cadherin
transcriptional repressors Slug, TCF3, and ZFHX1A (data not
shown). As expected, restoration of VHL reduced the expres-
sion of HIF target genes, VEGF and GLUT-1, and increased
E-cadherin expression (Fig. 5A; compare with results shown in
Fig. 2). These results suggest the possibility that VHL may
increase the expression of E-cadherin by down-regulating the
transcriptional repressors Snail and SIP1. In a complementary
experiment, we tested the ability of VHL in the transactivation
of E-cadherin promoter-driven luciferase reporter (Fig. 5B).
As expected, E-cadherin promoter containing both E2 boxes
had lower basal transcriptional activity relative to E-cadherin
promoter with point mutations in the E2 boxes that abrogate
Snail/SIP1 binding (Fig. 5B). Importantly, the addition of VHL
markedly increased the wild-type E-cadherin promoter-driven
luciferase transcription, but had insignificant effect on the E2
mutant E-cadherin promoter (Fig. 5B). As predicted, the in-
crease in VHL-mediated transactivity of wild-type E-cadherin
promoter-luciferase was dampened by the addition of SIP1
or/and Snail in a dosage-dependent manner (Fig. 5C). Coex-
pression analysis indicated that Snail or SIP1 had negligible
effect on the steady-state level of VHL (see Fig. S3 in the
supplemental material; also data not shown). These results
demonstrate that the E2 boxes are functionally important in
upregulating E-cadherin transcription by VHL, in part, via the
down-regulation of SIP1 and/or Snail. However, neither SIP1
nor Snail individually or in combination achieved a complete
inhibition of E-cadherin promoter-driven reporter activity.
This suggests that there exist other yet-to-be-defined VHL/
HIF-mediated E-cadherin-specific transcriptional repressors
or that full repression requires the concerted actions of mul-
tiple repressors and involves, in addition to the E2 boxes, other
elements within the E-cadherin promoter.
FIG. 4. VHL regulation of E-cadherin is HIF mediated. (A) RCC4-VHL cells were maintained under normoxia (N; 21% O2) or hypoxia (H;
1% O2) for 16 h, lysed, resolved on SDS-PAGE, and immunoblotted with anti-HIF-2, anti-E-cadherin, and anti-HA antibodies. (B) 786-O cells
stably expressing HA-VHL(WT), HA-VHL(C162F), or HA-VHL(L188V) were lysed, resolved on SDS-PAGE, and immunoblotted with the
indicated antibodies, where -tubulin served as an internal loading control. (C) 786-MOCK and 786-VHL cells infected with “empty” retrovirus
(786-VHLEMPTY) or retrovirus expressing constitutively stable and functional HIF-2(P531A) were lysed, resolved by SDS-PAGE, and
immunoblotted with the indicated antibodies, where -tubulin served as an internal loading control. Signal intensities were quantified using a Kodak
Image Station 2000R densitometer and normalized against the corresponding -tubulin signals; results are given in parentheses. Experiments were
performed three times with one representative experiment presented. (D) 786-O (VHL/) subclones stably expressing pRetroSUPER-empty or
pRetroSUPER-HIF2 shRNA were lysed, and comparable amounts of whole-cell extracts were immunoprecipitated and immunoblotted with an
anti-E-cadherin antibody. Equal amounts of the whole-cell extracts were also resolved on SDS-PAGE and immunoblotted with anti-HIF-2 and
anti-actin antibodies. Experiments were performed three times with one representative experiment presented. (E) Dual-luciferase assays were
performed in 786-MOCK and 786-VHL cells transfected with the firefly luciferase construct (E-cad prom-luc) driven by the human E-cadherin
promoter sequence. Cytomegalovirus-driven Renilla luciferase was used as an internal transfection control, and the firefly luciferase RLUs were
normalized against Renilla luciferase RLUs. Experiments and transfections were performed in triplicate with one representative experiment
presented. Error bars represent standard deviations. IP, immunoprecipitation; IB, immunoblot.
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Wild-type, but not CC-RCC-causing mutant VHL, induces
transcriptional activation of E-cadherin. The principal mech-
anism by which transcriptional repressors attenuate the rate of
transcription is by blocking the engagement of RNA Pol II and
associated factors to the promoter. Notably, Snail has been
shown to repress E-cadherin expression through the binding of
Sin3A/histone deacetylase 1 and 2 complex (52), which is
thought to impair recruitment of Pol II and transcriptional
initiation via repressive changes in chromatin structure. Re-
pressors can also act at a postinitiation step of transcription
including inhibition of phosphorylation of the Pol II holoen-
zyme, which represents a key step in promoter escape and
cessation in elongation (40). Therefore, we asked whether the
engagement of Pol II on the endogenous E-cadherin promoter/
gene is influenced by VHL. ChIP assays at the E-cadherin locus
were performed using antibodies recognizing the N terminus
of Pol II in 786-O cells expressing wild-type or an HIF regu-
lation-defective mutant VHL(C162F) (Fig. 6A). The total
amount of Pol II at the E-cadherin promoter and exon 10 was
dramatically decreased in the absence of VHL functional ac-
tivity (Fig. 6A). This was in contrast to the promoter of the
housekeeping gene, cyclophilin A, where binding of Pol II was
similar in wild-type and mutant VHL cells (Fig. 6A). This
suggests that VHL’s functional activity to negatively regulate
HIF is necessary for transcriptional activation of E-cadherin.
To further establish a functional role of VHL/HIF in E-
cadherin gene transcription, 786-O cells stably expressing wild-
type VHL were exposed to hypoxia. Assessment of Pol II
binding to genomic regions corresponding to coding regions of
E-cadherin (exon 10) revealed that hypoxia decreased E-cad-
herin transcription (Fig. 6B). A similar decrease in Pol II bind-
ing was demonstrated at the promoter of E-cadherin (data not
shown). As expected, hypoxia elicited a time-dependent in-
crease in VEGF mRNA expression (Fig. 6B). Taken together,
these results suggest that VHL activity, specifically E3 ligase
function to negatively regulate HIF, is required for the tran-
scription of the E-cadherin gene. Conversely, cellular hypoxia
or loss of HIF-associated function of VHL results in the acti-
vation of HIF and disengagement of Pol II from the E-cadherin
promoter, resulting in the down-regulation of E-cadherin tran-
scription. However, it is not formally known whether HIF-
mediated engagement of Pol II on E-cadherin promoter is
strictly SIP1/Snail-dependent.
E-cadherin expression is cell density dependent. E-cadherin
expression in CC-RCC cells is also cell density dependent as
measured by Western blotting and quantitative real-time PCR
(see Fig. S4A and B in the supplemental material). Interest-
ingly, the expression of VHL is strictly regulated by cell density
where the steady-state amount of VHL in human renal prox-
imal tubule epithelial cells was shown to increase more than
100-fold in dense cultures relative to sparse cultures (3). In
addition, other components of the VHL E3 ligase complex
showed a similar cell density-dependent regulation (44). Im-
portantly, HIF-2 level was elevated in sparsely growing cells
with low levels of VHL and significantly reduced or undetect-
able in confluent cells containing abundant VHL (44). More-
FIG. 5. VHL-mediated transcription of E-cadherin is attenuated by Snail and SIP1 via the conserved E2 boxes. (A) Expression levels of
E-cadherin, Snail, SIP1, VEGF, and GLUT-1 were measured by quantitative real-time PCR in 786-MOCK and 786-VHL cells and normalized to
U1AsnRNP1 mRNA expression. Solid bars represent expression of the indicated mRNA in 786-MOCK cells relative to its expression in 786-VHL
cells, which was arbitrarily set to 1.0. (B) Dual-luciferase assays were performed in U2OS cells transfected with the indicated expression plasmids.
The firefly luciferase construct (E-cad prom-luc) was driven by the human E-cadherin promoter sequence (WT) or the promoter with point
mutations in both E2 boxes (mutE2). Cytomegalovirus-driven Renilla luciferase was used as an internal transfection control, and the firefly
luciferase RLUs were normalized against Renilla luciferase RLUs. Experiments and transfections were performed in triplicate with one repre-
sentative experiment presented. Error bars represent standard deviations. (C) The experiment was performed as described in panel B with
increasing concentrations of Snail and SIP1 individually mixed into HA-VHL transfection reactions at a ratio of 1:2, 2:2, and 4:2 (Snail or
SIP1:HA-VHL) or equal quantities of SIP1 and Snail combined into HA-VHL transfection reactions at a ratio of 1:1 (Snail and SIP1:HA-VHL).
Relative increases in induction (n-fold) were standardized to the E-cad prom-luc activity in the absence of exogenous VHL.
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over, the ability of VHL to shuttle between the nucleus and the
cytoplasm is also regulated by cell density (37), which in turn
may influence the ability of VHL to regulate HIF activity (20).
Thus, cell density-dependent expression of E-cadherin may be
due to a corresponding cell density-dependent regulation of
VHL stability/function.
DISCUSSION
VHL is a direct oxygen-dependent negative regulator of
HIF via the ubiquitin-proteasome pathway (29). The loss
of VHL or VHL mutations associated with the development of
CC-RCC invariably results in the accumulation/hyperactiva-
tion of HIF due to a failure in VHL’s ability to either bind or
ubiquitylate HIF. Here, we propose that HIF—stabilized by
hypoxia in the presence of wild-type VHL or upon mutation/
loss of VHL—activates the transcriptional repressors SIP1 and
Snail (likely via the HIF-engagement of the hypoxia-responsive
element 5-GCGTG-3 found in the Snail promoter at position
86 to 82; SIP1 promoter/enhancer has not been defined),
preventing Pol II engagement on the E-cadherin promoter and
resulting in the down-regulation of E-cadherin expression (Fig.
7). There is, however, an additional pathway to consider (de-
scribed below).
Increased transforming-growth factor  (TGF-) signaling
and expression of Snail and SIP1, as well as the loss of E-
cadherin expression, have all been correlated with the epithe-
lial to mesenchymal transition process that occurs during nor-
mal development and acquisition of invasive phenotype in
epithelial cancers (5, 10, 13, 64). Smad-mediated signaling by
TGF- has been shown to induce the expression of the repres-
sors Snail and SIP1 (13, 27, 60). HIF-1 has been shown to
upregulate the expression of the members of TGF- family in
a transcription-dependent manner under hypoxic conditions.
HIF-1 and Smad proteins cooperate in regulating the expres-
sion of several hypoxia and TGF--regulated genes, including
the expression of TGF-2 in human umbilical vein endothelial
FIG. 6. VHL activity is required for E-cadherin transcription. (A) ChIP using anti-RNA Pol II antibody was performed on sheared chromatin
from 786-O cell lines (VHL/) that had been stably transfected with wild-type VHL (open bar) or mutant VHL(C162F) (solid bar). IP DNA was
determined for the promoter and exon 10 of E-cadherin and the promoter of cyclophilin A using real-time PCR, and the value in VHL(WT) cells
was arbitrarily set to 1.0. (B) RNA Pol II ChIPs were performed in 786-VHL(WT) cells exposed to 4 or 20 h of hypoxia (1% oxygen). IP DNA
for exon 10 of E-cadherin was normalized to the IP DNA for the cyclophilin A promoter (left). Normoxia was arbitrarily set to 1.0. Expression of
VEGF was assessed by real-time PCR as internal control for hypoxia treatment (right).
FIG. 7. VHL gatekeeper’s pathway in renal epithelium. See text for
details.
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cells (67). In addition, HIF-1 has been shown to directly bind
to the TGF-3 promoter and upregulate its expression under
hypoxia during placental and epithelial development processes
(47, 57). Therefore, increased transcriptional activity of HIF by
the functional loss of VHL in CC-RCC may result in an up-
regulation of TGF- signaling, resulting in a Smad-mediated
induction of SIP1 and Snail and subsequent loss of E-cadherin
(Fig. 7). Notably, VHL has also been shown to repress the
expression of TGF-1 by regulating its mRNA stability (Fig. 7,
dashed line) (2). Whether this process is HIF mediated is
currently unknown.
In the current work, we demonstrated that the loss of VHL
leads to the dramatic down-regulation of E-cadherin in CC-
RCC. VHL-dependent transactivation of E-cadherin was de-
pendent on the conserved E2 boxes known to recruit transcrip-
tional repressors Snail and SIP1 to the promoter of E-cadherin.
Reintroduction of VHL in CC-RCC cells devoid of VHL
showed a reduction in the expression of both Snail and SIP1,
thereby explaining, at least in part, the resulting restoration of
E-cadherin expression. Transcriptional repressors principally
block transcription by inhibiting the engagement of Pol II to
the promoter. In support, Snail has been shown to repress
E-cadherin expression through the binding of histone deacety-
lase, promoting repressive changes in chromatin structure and
thereby impairing the recruitment of Pol II and transcription
(52). Consistent with this view, wild-type VHL enhanced the
recruitment of Pol II to the E-cadherin promoter/gene,
whereas hypoxia or a tumor-causing VHL mutant with a fail-
ure in targeting HIF for ubiquitin-mediated destruction dra-
matically decreased the association of Pol II with the E-cad-
herin gene. Thus, VHL or functional hypoxia directly affects
Pol II engagement on E-cadherin DNA likely via HIF-depen-
dent regulation of E-cadherin-specific transcriptional repres-
sors, revealing a previously unrecognized regulation of a major
epithelial tumor suppressor E-cadherin.
During the preparation of the present report, Krishnamachary
et al. and Esteban et al. showed that the loss of VHL in
CC-RCC cells results in the loss of E-cadherin expression in a
HIF-dependent manner (16, 34). Krishnamachary et al. argue
that the regulation of E-cadherin expression is exclusively
HIF-1 dependent, as 786-O (HIF-1 /) cells failed to express
E-cadherin after VHL rescue (16, 34). However, our data
clearly demonstrate that HIF-2, in the absence of HIF-1, can
restore E-cadherin expression upon reintroduction of VHL in
786-O cells. Although the reason for this discrepancy is un-
clear, the relative contribution of HIF-1 versus HIF-2 in the
development of CC-RCC is an emerging area of research. For
example, the introduction of a HIF-1 mutant that escapes
VHL recognition into CC-RCC cells reconstituted with wild-
type VHL does not produce a tumorigenic phenotype in SCID
mice (41). However, the treatment of these VHL-restored
CC-RCC cells with an HIF-1-oxygen-dependent degradation
domain peptide that can block VHL binding to HIF sub-
strates restored the tumorigenic phenotype (41). This finding
suggests that although HIF-1 is dispensable, other HIF sub-
units (or possibly other ECV substrates) are associated with
the tumor suppressor function of VHL. In support of this
notion, Kondo et al. demonstrated that, unlike HIF-1, the
nondegradable HIF-2 was able to restore the tumor pheno-
type in CC-RCC cells expressing wild-type VHL (32), suggest-
ing that HIF-2 is the relevant oncogenic player in the devel-
opment of CC-RCC. Furthermore, Rankin et al. used the
PEPCK (phosphoenolpyruvate carboxykinase) promoter to
generate transgenic mice in which Cre-recombinase is ex-
pressed in the renal proximal tubules and hepatocytes (54).
Conditional inactivation of VHL in PEPCK-Cre mouse re-
sulted in glomerular and tubular renal cysts, increased serum
erythropoietin levels, and polycythemia (54). The inactivation
of ARNT, but not HIF-1, rescued the conditional VHL
knockout mouse from developing renal cysts (53, 54), further
supporting the notion that another partner of ARNT such as
HIF-2, but not HIF-1, plays a critical role in the transfor-
mation of renal proximal tubules.
We show here that the depletion of E-cadherin promotes the
invasive potential of VHL-reconstituted CC-RCC cells, which
is in keeping with the canonical function of E-cadherin.
Krishnamachary et al. recently provided evidence that loss of
VHL promotes epithelial-mesenchymal transformation, which
is consistent with a loss of adherens junction due to reduced
E-cadherin expression (34). There are, however, other notable
VHL-dependent events bearing on CC-RCC progression to
consider. CXCR4 is a chemokine receptor that aids in the
metastasis of tumor cells to organs abundant in CXCR4-spe-
cific ligand, stromal cell-derived factor-1 (SDF-1). Staller et
al. showed that the expression of chemokine receptor CXCR4
increases upon the loss of VHL, suggesting a potential mech-
anism of CC-RCC metastasis (61). In addition, Zagzag et al.
recently demonstrated that CC-RCC and hemangioblastoma
cells devoid of VHL overexpress not only CXCR4 but also its
ligand SDF-1 (66). These findings suggest that loss-of-func-
tion of VHL can establish an autocrine signaling pathway pro-
viding selective survival advantage and increased tendency for
metastasis. The impact of the individual events (i.e., VHL-
mediated E-cadherin versus CXCR4/SDF-1 regulation) in
CC-RCC progression is not yet established, but nevertheless
remains an important question to address.
In addition, VHL binds directly to fibronectin and promotes
proper assembly of fibronectin extracellular matrix (ECM) (21,
50). All disease-associated VHL mutants examined to date
exhibit decreased or undetectable binding to fibronectin (21,
50), underscoring the importance of VHL-mediated fibronec-
tin assembly in the pathogenesis of VHL disease. In fact, al-
terations in the fibronectin component of the ECM have been
correlated with cellular transformation (22). Conversely, mul-
timeric forms of fibronectin or the overproduction of fibronec-
tin receptors, such as 51 integrin, have been shown to
promote differentiation and suppress the proliferative and
metastatic potentials of transformed cells in various model
systems (22, 51, 56). Lieubeau-Teillet et al. demonstrated that
CC-RCC cells lacking VHL grow as tightly packed amorphous
spheroids in a three-dimensional growth assay, indicative of an
undifferentiated phenotype (38). In contrast, CC-RCC cells
reconstituted with VHL form loose aggregates, which, on mi-
croscopic and ultrastructural examination, exhibit evidence of
epithelial differentiation, such as trabecular and tubular struc-
tures (38). Davidowitz et al. demonstrated that VHL express-
ing CC-RCC cells grown on ECM differentiate into organized
epithelial monolayers, whereas VHL-deficient cells are branched
and disorganized and fail to arrest under high cell density (14).
Koochekpour et al. showed that CC-RCC cells lacking functional
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VHL produce increased levels of matrix metalloproteinases and
attenuated levels of tissue inhibitors of metalloproteinases and
demonstrate increased invasiveness on growth factor-reduced
matrigel (an artificial ECM) in response to hepatocyte growth
factor/scatter factor (33). The lack of functional VHL has also
been associated with overproduction of carbonic anhydrases 9
and 12, which are involved in the acidification of the microenvi-
ronment, favoring the growth and invasive properties of tumor
cells (25, 42, 59). Thus, in addition to regulating E-cadherin ex-
pression, VHL is seemingly required for multiple additional
events governing epithelial transformation from cellular differen-
tiation to invasiveness.
There are other examples of cancer-causing mutations that
often increase the expression of HIF, which provides a mech-
anistic explanation for hypervascular tumors including CC-
RCC that develop in the absence of VHL mutations. Mutations
in the TSC2 tumor suppressor gene increase the level of HIF
via the mammalian target of rapamycin-dependent and -inde-
pendent mechanisms that may involve chromatin remodeling
(9). Loss of PTEN, which has been observed in the brain tumor
glioblastoma multiforme, results in increased HIF-1 levels via
the activation of the Akt/protein kinase B signaling cascade
(68). The increased expression of HER2 receptor tyrosine ki-
nase in breast cancer and the loss of p53 in various tumors
enhance HIF-1-dependent transcription, often correlating with
tumor aggressiveness (36, 55). Although these examples sup-
port the notion that there are multiple important regulators of
HIF to ultimately promote oncogenic transformation, whether
non-VHL-associated HIF activation likewise results in the
down-regulation of E-cadherin via the activation of SIP1/Snail
family of transcriptional repressors is an important question
that remains to be resolved.
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